Navigation Links
Anchoring ABL for a better fate
Date:8/27/2013

Chronic Myelogenous Leukemia (CML) is a cancer of the white blood cells that is most commonly found in adults and in the elderly. Its incidence has been estimated to be 1 to 2 in 100,000 people. CML was the first cancer to be associated with a genetic abnormality, known as the Philadelphia Chromosome, which 95% of all CML patients carry in their cells.

The Philadelphia Chromosome is formed by exchanges of material belonging to two distinct chromosomes, number 9 and number 22. To form the Philadelphia Chromosome, these two chromosomes break at very specific places, disrupting the BCR (in chromosome 22) and the ABL (in chromosome 9) genes that were otherwise normal. Juxtaposition of these two genes in the Philadelphia Chromosome creates an abnormal kinase tyrosine known as BCR/ABL, which is an enzyme associated with cell regulation. The Philadelphia Chromosome is associated with loss of cell control and presence of immortal cells, which leads to cancer.

In the 1990s, ST1-571 (known as imatinib or Gleevec), a new inhibitor of kinase tyrosine, was developed and tested against CML cells. Since then, the drug has been used as the first line of treatment in many patients, increasing survival rates and improving patients' quality of life. However, some patients develop resistance to the drug, which has fostered development of novel drugs that act on alternative sites on the BCR/ABL enzyme.

Aiming to gain in-depth knowledge about the mechanisms involved in ABL control in normal cells, a group led by Dr. Jerson Silva at the Federal University of Rio de Janeiro, Brazil used small angle X-ray scattering, nuclear magnetic resonance, and confocal microscopy to investigate the dynamics of the entire ABL regulatory unit. The study shows that activation of the protein releases intramolecular interactions between a regulatory unit found in the N-terminal region of the ABL, the so-called N Cap, and a number of molecular modules, and pushes ABL to anchor on the cell membrane. The whole complex undergoes motions lasting micro- to milliseconds that ultimately result in the death of the cell.

The study also reveals that changes in the N-terminal region, or its absence, are associated with the entire cell escaping apoptosis, the mechanism responsible for cell death. With no apoptosis, cells become immortal and cancer strikes.

The finding has major implications for CML research as it has been known for some time that CML cells are resistant to apoptosis and that, unlike their normal counterparts, they are not found anchored to the cell membrane but loose in the cell cytoplasm. According to Guilherme A. P. de Oliveira, the first author of the study, "our findings indicate that the ABL regulatory unit is involved with the right localization of the enzyme in the cell, dictating the fate of the cell."

The results also gain further importance in the light of recent studies showing that ABL kinases have enhanced expression and activity in some solid tumors.


'/>"/>

Contact: Jerson Lima Silva
jerson@bioqmed.ufrj.br
55-212-562-6756
Publicase Comunicao Cientfica
Source:Eurekalert

Related medicine news :

1. Diet Doc Now More Closely Tailors Its Medically Supervised Diet Plans Around Individual Patient Need, Providing an Opportunity to Live Longer & Feel Better Naturally
2. MillionaireMatch.com Develops New Mobile Apps Enabling Members To Attain Better Dating Service
3. Natural Body Defense Fights Inflammation Better With Its Improved All-natural Content
4. Nursing professor receives funding to better estimate child fatalities due to abuse and neglect
5. Elena Shea’s New Book Reveals Guide to Building Vitality for Better Health
6. Pionetics® Corporation Celebrates Water Quality Month by Sharing Passion for Better Drinking Water
7. New survey of young adults: 7.8 million gained new or better coverage through Affordable Care Act
8. Golf Fitness
9. How “Power Golf Training” Helps People Get Better Physical Health to Play Golf – Vinamy
10. Flexibility Exercises
11. How “Ageless Mobility” Helps People Get Better Physical Health - Vinamy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 2016 , ... Compliancy Group LLC is pleased to offer ... the country. The Guard was specifically designed to handle each element required for ... updates, and compliance coaching. , In addition to meeting the compliance needs of ...
(Date:2/10/2016)... ... February 10, 2016 , ... Emergency rooms provide emergency care to stabilize ... can leave patients with dental emergencies at risk of losing a tooth or their ... care. , Common dental emergencies include:, , Avulsed or ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. ... office is now offering a variety of comprehensive procedures for facial enhancement. The ... facial volume restoration, lip enhancement and nasal reshaping. , As a result, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ravages of ... (ALCA) to conduct a survey that takes a closer look at cases of TBI ... prevalence and causes of TBI among the aging population, and identifies the challenges associated ...
(Date:2/10/2016)... Indianapolis, IN (PRWEB) , ... February 10, 2016 ... ... employee benefits advisory organization, welcomes S.S. Nesbitt as the latest addition to its ... and has seven other locations throughout the Southeast, from Orlando to Huntsville and ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016  LexisNexis® Risk ... technology, today announced the launch of LexisNexis ... solution that helps improve and optimize the quality ... of performance using severity-adjusted scores. By measuring provider ... critical solution to deliver better outcomes, improve the ...
(Date:2/10/2016)... Calif. , Feb. 10, 2016 /PRNewswire/ ... a synergistic confluence of various technologies that ... propositions, previously unavailable. These opportunities create a ... convergence, in turn, drives the development of ... scenario is characterized by technology convergences, which ...
(Date:2/10/2016)... 2016 Mast Therapeutics, Inc. (NYSE ... for sickle cell disease and heart failure, today announced ... units at a price to the public of $0.275 ... the Company,s common stock and one warrant to purchase ... exercise price of $0.42 per share. The warrants are ...
Breaking Medicine Technology: